Phaseline

Targets › VZVE

VZVE: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 4; Immunology; next expected readout Jun 2032.

Open in Phaseline: the race on VZVE, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University of Sao Paulo General HospitalRecombinant Herpes Zoster Vaccine (RZV/Shingrix®)
Recombinant VZV glycoprotein E with AS01B adjuvant system
VZVEPhase 4Rheumatoid ArthritisJun 2032

Conditions

Rheumatoid Arthritis (1)

Modalities

other (1)

Companies

University of Sao Paulo General Hospital (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.